Immuneering Corporation
IMRXImmuneering Corporation is a late-stage clinical biotechnology company developing a new class of anti-cancer medicines called Deep Cyclic Inhibitors (DCI).
Table of contents
Earnings
Next report
Aug 12, 2026 (in a month)Competitors
By market cap
By revenue growth
Profile
Immuneering Corporation is a late-stage clinical biotechnology company developing a new class of anti-cancer medicines called Deep Cyclic Inhibitors (DCI). The company leverages a proprietary bioinformatics platform and 3D tumor modeling to create small molecule therapies that target core signaling pathways, such as MAPK, with the goal of improving drug durability and patient tolerability compared to traditional precision therapies.
Immuneering is a pioneer in Deep Cyclic Inhibition, positioning itself as a differentiated player in the MAPK pathway space by focusing on signaling dynamics rather than chronic inhibition.
Questions, answered.
- What is Immuneering Corporation's market cap?
- Immuneering Corporation (IMRX) has a market capitalization of $346.8M and trades on NASDAQ.
- Who are Immuneering Corporation's competitors?
- Immuneering Corporation's key competitors include Novartis AG, Pfizer Inc., Bullfrog AI Holdings, Inc. Common Stock, and others. These companies compete in similar markets and product categories.
- Who does Immuneering Corporation partner with?
- Immuneering Corporation's notable partners include Regeneron Pharmaceuticals, Inc..
- Where is Immuneering Corporation headquartered?
- Immuneering Corporation is headquartered in United States of America and employs approximately 65 people. It has been publicly traded since 2021.